Sir -We read with interest the guest editorial by Hart and Easty (Br. J. Cancer, 1991, 63, 9-12) , on the approaches to the identification and isolation of genes responsible for determining the metastatic phenotype, and wish to add further information regarding a specific gene highlighted in the review.
Expression of the anti-metastatic gene nm23 has been shown to correlate with the known metastatic potential of cell lines in murine and rat tumour models. Cotransfection of rat embryo fibroblasts (REF) with the ras oncogene and the adenovirus 2 Ela gene was associated with higher levels of nm23 expression compared to the REF cell lines which were transfected with the metastasis inducing ras oncogene alone (Steeg et al., 1988) . Two clones of the human nm23 gene have been identified which are located on chromosome 16 and 17 , regions of the latter are commonly deleted in breast cancer and contain the p53 and HER2/neu gene loci.
The possible function of the Nm23 protein in tumour metastasis is discussed in the review. However, more recent work has given further information, with the Awd/Nm23 protein being identified by immunoblotting in cultured Drosophila cells, zebra fish embryos, cultured mouse cells, and demonstrated in Drosophila microtubule preparations (Biggs et al., 1990) . Loss of the Nm23 protein may therefore cause defects in mitosis and/or protein synthesis due to disruption of spindle microtubule polymerisation. The exact mechanism by which the metastatic phenotype may be controlled by the Nm23 protein remains unresolved.
In a limited series of 24 benign and malignant human breast tumours, nm23 expression was assessed by mRNA hybridisation and in situ hybridisation, and high levels of nm23 expression were associated with an absence of lymph node metastases (Bevilacqua et al., 1989) , leading the authors to suggest that the nm23 gene may suppress the metastatic phenotype.
We have asssessed the level of nm23 expression in human primary breast cancers, using the murine pnm23-1 plasmid and found there was differential expression of the nm23 gene, with a variation of 120-fold (Hennessy et al., 1991) . nm23 mRNA levels from 145 tumours have shown a significant inverse relationship with lymph node involvement: of 63 tumours from lymph node positive patients 39 (62%) demonstrated low levels of expression, whereas only 19 out of 46 tumours (41%), from lymph node negative patients, had similarly low levels (P = 0.032). Low levels of nm23 expression were seen in poorly differentiated tumours (P = 0.027) and in oestrogen receptor negative tumours (P =0.054). There were no significant correlations between nm23 mRNA expression and tumour size, epidermal growth factor receptor status, or menopausal status. Also of interest is that there was no significant correlation between nm23 and HER2/neu or p53 oncoprotein expression. In the 70 patients who have been followed-up for greater than 2 years, loss of nm23 expression was associated with disease recurrence (P = 0.003) and poor patient survival (P = 0.005), and was second only to nodal status as a significant prognostic variable. We agree therefore that expression of the nm23 gene may be an important marker for predicting tumour metastasis and outcome of disease; perhaps identifying a group of patients who might benefit from adjuvant therapy. 
